Shedding Light on PARP Inhibitor Response through Functional Imaging.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
14 04 2023
Historique:
received: 19 12 2022
revised: 06 01 2023
accepted: 19 01 2023
medline: 17 4 2023
pubmed: 27 1 2023
entrez: 26 1 2023
Statut: ppublish

Résumé

Functional PET imaging using a PARP inhibitor (PARPi) analog may serve as an early, dynamic biomarker of response to PARPi therapy in high-grade serous ovarian cancer. Clinically, this could help to rapidly identify PARPi nonresponders, thereby maximizing efficacy and avoiding toxicities of futile treatments. See related article by Pantel et al., p. 1515.

Identifiants

pubmed: 36700799
pii: 716223
doi: 10.1158/1078-0432.CCR-22-3711
pmc: PMC10106371
mid: NIHMS1867162
doi:

Substances chimiques

Poly(ADP-ribose) Polymerase Inhibitors 0
Antineoplastic Agents 0
Biomarkers 0

Types de publication

Editorial Research Support, N.I.H., Extramural Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

1384-1386

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentOn

Informations de copyright

©2023 American Association for Cancer Research.

Références

Ann Oncol. 2022 Oct;33(10):1021-1028
pubmed: 35772665
Nat Commun. 2021 May 3;12(1):2487
pubmed: 33941784
Gynecol Oncol. 2022 Sep;166(3):425-431
pubmed: 35803835
Cancer Res. 2016 Aug 1;76(15):4516-24
pubmed: 27261505
Lancet Oncol. 2021 May;22(5):620-631
pubmed: 33743851
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Lancet Haematol. 2021 Feb;8(2):e122-e134
pubmed: 33347814
J Clin Oncol. 2010 May 20;28(15):2512-9
pubmed: 20406929
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Gynecol Oncol. 2021 Nov;163(2):246-253
pubmed: 34620496
Clin Cancer Res. 2023 Apr 14;29(8):1515-1527
pubmed: 36441795
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
J Clin Oncol. 2022 Nov 20;40(33):3878-3881
pubmed: 36150092

Auteurs

Ying L Liu (YL)

Division of Gynecological Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical College, New York, New York.

Dmitriy Zamarin (D)

Division of Gynecological Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical College, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH